SGMT Stock Summary and Trading Ideas (Sagimet Biosciences - Series A | NASDAQ:SGMT)

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Sagimet Biosciences - Series A trades on the NASDAQ stock market under the symbol SGMT.

As of February 4, 2026, SGMT stock price declined to $6.08 with 898,272 million shares trading.

SGMT has a beta of 3.44, meaning it tends to be more sensitive to market movements. SGMT has a correlation of 0.28 to the broad based SPY ETF.

SGMT has a market cap of $197.73 million. This is considered a Micro Cap stock.

The top ETF exchange traded funds that SGMT belongs to (by Net Assets): VTI, VXF, IBB, IWC, AVSC.

SGMT has outperformed the market in the last year with a return of +30.5%, while the SPY ETF gained +16.0%. However, in the most recent history, SGMT shares have underperformed the stock market with its stock returning -24.6% in the last 3 month period and -3.2% for the last 2 week period, while SPY has returned +0.7% and +1.3%, respectively.

SGMT support price is $6.21 and resistance is $6.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SGMT shares will trade within this expected range on the day.